XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:          
Net income (loss) $ 609 $ 655 $ 1,902 $ 1,995  
Adjustments to reconcile net income (loss) to net cash flows from operating activities:          
Depreciation, depletion and amortization     804 742  
Changes in assets and liabilities:          
Receivables     (516) (522)  
Accounts payable     (145) 137  
Inventories     16 (413)  
Other operating activities     232 109  
Total cash flows provided by operating activities     2,409 2,048  
Cash flows from investing activities:          
Capital expenditures     (1,016) (980)  
Payments to Acquire Marketable Securities     (320) (301)  
Proceeds from sales of property, plant and equipment     149 136  
Other investing activities     (160) (91)  
Total cash flows used in investing activities     (1,210) (1,124)  
Cash flows from financing activities:          
Dividends to shareholders     (452) (433)  
Repayments of Long-term Debt     0 (150)  
Payments for Repurchase of Common Stock     696 546  
Other financing activities     (37) 2  
Total cash flows used in financing activities     (1,185) (1,127)  
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations     (100) (107)  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total     (86) (310)  
Cash and equivalents at beginning of period $ 2,264 $ 2,346 2,264 2,346 $ 2,346
Cash and equivalents at end of period         2,264
Cash and equivalents at end of period     2,178 2,036 $ 2,264
Cash payments during the period for:          
Interest     336 355  
Income taxes     $ 369 528  
Maximum Percentage Gross Trade Receivables From One Customer     10.00%   10.00%
Proceeds from Sale and Maturity of Marketable Securities     $ 137 112  
Impairments and other charges [1]     $ 116 $ 0  
UNITED STATES | Accounts Receivable [Member] | Geographic Concentration Risk [Member]          
Cash payments during the period for:          
Concentration Risk, Percentage     30.00%   33.00%
MEXICO | Accounts Receivable [Member] | Geographic Concentration Risk [Member]          
Cash payments during the period for:          
Concentration Risk, Percentage     12.00%   9.00%
[1]
For the three and nine months ended September 30, 2024, the amount includes a $45 million charge attributable to Completion and Production, a $34 million charge attributable to Drilling and Evaluation, and a $37 million charge attributable to Corporate and other. See Note 2 for further discussion on impairments and other charges.